GAITHERSBURG, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. Altimmune management will host a conference call at 8:30 am E.T. on February 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. ...

Altimmune (NASDAQ: ALT ) is approaching a pivotal moment in 2025, one that could redefine its future. I believe Altimmune offers a compelling risk-reward profile, and as such, I am long the stock - mindful of the inherent risks tied to thisHelixberg is an independent biotech publication dedicated to providing concise and insightful briefings on major biotech catalysts and portfolio strategies. As a seasoned healthcare professional with extensive experience in the biotech sector and hedge fund industry, I fo ...

GAITHERSBURG, Md., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference. Details are as follows: Conference:Guggenheim SMID Cap Biotech Conference Date/Time:Wednesday, February 5, 2025, at 9:30 a.m. EST The session will be webcast and can be accessed by visiting the Events section of the Altimmune websit ...

Company Analysis - Altimmune's incretin drug, pemvidutide, shows promising prospects [1] - The company is awaiting the outcome of its end-of-phase 2 (EOP2) meeting with the U.S. FDA [1] Industry Focus - The biotech industry is heavily influenced by trial results and NDA/BLA approvals [2] - Companies in industries regulated by the FDA are a key focus area [2]

Altimmune (ALT 3.54%) had some encouraging news to share with the world as the trading week drew near a close on Thursday. The biotech announced that it will soon ascend to an important, specialized stock index; investors greeted this news by trading the company's stock up by more than 3% on the day. This provided quite a marked contrast to the general trend for stocks, as the S&P 500 index dipped marginally across the session.Inclusion in an industry indexBefore market open, Altimmune divulged that it is b ...

GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) effective prior to the market open on Monday, December 23, 2024. “Our addition to the NBI is an important recognition to conclude what has been a year of major progress for the Company,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “With a number of significant in ...

Company Overview - Altimmune is a small-cap biotech company focused on developing a GLP-1/Glucagon dual-agonist peptide called Pemvidutide [1] - The company has pivoted multiple times in its history but is now targeting the obesity and MASH (metabolic dysfunction-associated steatohepatitis) markets [1] Product Focus - Pemvidutide is a key product in the company's pipeline, aimed at addressing obesity and MASH [1] Market Strategy - The company is positioning itself in the growing markets of obesity and MASH, which are significant areas of unmet medical need [1]

Altimmune (ALT) is developing its lead candidate, pemvidutide, a novel, investigational and peptide-based GLP-1/glucagon dual receptor agonist for treating obesity and metabolic dysfunction-associated steatohepatitis (MASH).The company has made rapid progress with the development of pemvidutide, which has pushed up its stock price in recent months. A phase IIb IMPACT study is ongoing which is evaluating pemvidutide for the treatment of patients with biopsy-confirmed MASH.Last month, Altimmune completed the ...

Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids Findings support the potential benefit of pemvidutide on co-morbidities of metabolic dysfunction-associated steatohepatitis (MASH), including atherosclerosis, heart disease and metabolic syndrome Pemvidutide is currently being evaluated in IMPACT, the Phase 2b trial in subjects with MASH; data readout expected in Q2 2025 GAITHERSBURG, Md., Nov. 15, 2024 (GLOBE NEWSWIR ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...